Rivaroxaban with Aspirin Versus Aspirin for Peripheral Arterial Disease and Intermittent Claudication. Rationale and Design of the COMPASS CLAUDICATION Trial

BACKGROUND: The COMPASS trial demonstrated that in patients with peripheral arterial disease, the combination of rivaroxaban and aspirin compared with aspirin reduces the risk of major adverse limb events, but it is not known whether this combination can also improve symptoms in patients with interm...

Descripción completa

Detalles Bibliográficos
Autores principales: Ramacciotti, Eduardo, Agati, Leandro Barile, Volpiani, Giuliano Giova, Brito, Karen Falcão, Ribeiro, Camilla Moreira, Aguiar, Valéria Cristina Resende, Ramacciotti, Lorenzo Storino, Paganotti, Alexia, Pereira, Felipe Menegueti, Caffaro, Roberto Augusto, Fioranelli, Alexandre, Krakauer, Rogério, Rached, Heron Rhydan Saad, Wolosker, Nelson, Anand, Sonia S., Eikelboom, John W., Lopes, Renato Delascio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Manuscript
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796110/
https://www.ncbi.nlm.nih.gov/pubmed/35043716
http://dx.doi.org/10.1177/10760296211073922

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8796110/
https://www.ncbi.nlm.nih.gov/pubmed/35043716
http://dx.doi.org/10.1177/10760296211073922

Ejemplares similares